609 Stock Chart & Stats
€3.93
>-€0.01(-0.18%)
At close: 4:00 PM EST
€3.93
>-€0.01(-0.18%)
Day’s Range― - ―
52-Week Range€1.78 - €4.92
Previous CloseN/A
Volume0.00
Average Volume (3M)221.00
Market Cap
€80.05M
Enterprise Value€133.34
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding43,736,416
10 Day Avg. Volume663
30 Day Avg. Volume221
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Defined ApoA-I/HDL Therapeutic PlatformA focused platform centered on apoA-I and HDL biology gives ABIONYX a coherent scientific direction across severe inflammatory and infectious indications. This concentration can support research depth and pipeline development over time, although commercial validation remains dependent on advancing candidates.
Revenue Above Historical Near-zero LevelsRevenue has progressed materially beyond the company’s earlier near-zero base, showing that some commercial or operational activity exists despite continued volatility. Maintaining and expanding this higher revenue level could improve operating leverage if development spending and other costs become more efficient.
Operating Cash Burn Improved Versus 2024The reduction in operating cash outflow compared with 2024 indicates some improvement in cash consumption, which could modestly extend financial runway if sustained. However, the benefit is limited because operating cash flow remains negative and does not yet demonstrate self-funding operations.
Bears Say
Declining Revenue And Sharply Weaker MarginsRecent revenue contraction and the sharp gross-margin decline weaken the economics of the business and reduce the contribution available to fund research and development. Unless revenue stabilizes and margins recover, the company may struggle to build a sustainable financial base from operations.
Large Operating Losses And Persistent Cash BurnVery large operating losses relative to revenue, together with sustained negative operating and free cash flow, show that the current business model is not self-financing. Continued losses can require repeated external funding and may constrain the pace or scope of future development activities.
Eroding Equity And Rising LeverageShrinking equity alongside rapidly higher debt-to-equity reduces financial flexibility and increases dependence on funding decisions while losses continue. The weaker balance sheet leaves less capacity to absorb setbacks or sustain investment without additional financing, potentially creating dilution or repayment pressure.
ABIONYX Pharma SA News
609 FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest stock price was €1.78 and its highest was €4.92 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €80.05M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 9 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.091 earnings per share for the quarter.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 43,736,416 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.091 in its last earnings report. Following the earnings report the stock price went down -2.841%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in DE:609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.